ADIAL PHARMACEUTICALS, INC. Quarterly Debt-to-equity in % from Q3 2021 to Q4 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Adial Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q4 2023.
  • Adial Pharmaceuticals, Inc. Debt-to-equity for the quarter ending December 31, 2023 was 36.7 %, a 8.75% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2023 36.7 -3.52 -8.75% Dec 31, 2023
Q3 2023 57 +11.6 +25.5% Sep 30, 2023
Q2 2023 57.4 +11.7 +25.5% Jun 30, 2023
Q1 2023 56.5 +4.25 +8.14% Mar 31, 2023
Q4 2022 40.2 -23.4 -36.7% Dec 31, 2022
Q3 2022 45.4 -5.44 -10.7% Sep 30, 2022
Q2 2022 45.7 Jun 30, 2022
Q1 2022 52.2 Mar 31, 2022
Q4 2021 63.6 Dec 31, 2021
Q3 2021 50.8 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.